Condition: Melanoma (Skin Cancer) · Nevi and Melanomas · Congenital Melanocytic Nevus · Sponsor: Fundacion Clinic per a la Recerca Biomédica
The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients.
This description comes directly from the study's public registry record.
Susana Puig Sardà, PhD, MD · +34932275400 · spuig@clinic.cat
Adrián López Canosa, PhD · lopez64@recerca.clinic.cat
Always discuss trial participation with your own doctor first.
| Hospital Clínic de Barcelona (Dermatology service) | Barcelona, Spain | Not Yet Recruiting |
| Hospital Clínic Barcelona | Barcelona, Spain | Recruiting |
| Hospital Clínic Barcelona | Barcelona, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06605443